医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Opinion for

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Receives Positive CHMP BRUKINSA Opinion for zanubrutinib

2022年09月19日

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Receives Positive CHMP BRUKINSA for the Treatment of Adults with Waldenström’s Macroglobulinemia Opinion for zanubrutinib

2021年09月17日

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ADCETRIS Brentuximab Vedotin Cyclophosphamide Opinion for Takeda Receives Positive CHMP

2020年03月31日

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ALUNBRIG as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer brigatinib Opinion for Takeda Receives Positive CHMP

2020年03月02日

Shionogi Receives Positive CHMP Opinion for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adult Patients With Limited Treatment Options

Shionogi Receives Positive CHMP Opinion for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adult Patients With Limited Treatment Options

バイオテクノロジーヘルスケア医療用品感染症臨床試験製薬　 TimeLine: cefiderocol FETCROJA for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adult Patients With Limited Treatment Options Opinion for Shionogi Receives Positive CHMP

2020年03月02日